An interventional study of Multilevel Hypertension Care Model in Hypertension, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by NYU Langone Health · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies in Hypertension by NYU Langone Health — 6 open to participants now, 7 under way, none of them phase 3. Hypertension · NYU Langone Health.
Among the 44 studies in Hypertension by NYU Langone Health, this one is the 10th largest by planned enrollment of the 39 interventional ones that give a count, is the only one that started in 2027, is one of 31 with no phase, and was the 44th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →6 of the 44 studies in Hypertension by NYU Langone Health are open now, in 2 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in Kenya
Ages 18+
NYU Langone Health · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 18–99 · Women only
NYU Langone Health · Sites in United States
Ages 18+
NYU Langone Health · Sites in United States
Ages 21+
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 1997; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 628 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 300 across the 39 interventional studies, 114 across the 5 observational. Of the 36 that completed or were terminated, 11 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
NYU Langone Health is the lead sponsor of 1,431 studies on the registry; 258 are open to participants now.
Of its 235 completed or terminated interventional studies of FDA-regulated products, 197 (84%) have results posted.
2 of the studies in Hypertension by NYU Langone Health that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06511479NYU Langone HealthJackson Heart Study Women's Hypertension Study | 2027-05-30 |
| NCT05208450NYU Langone HealthActions to Decrease Disparities in Risk and Engage in Shared Support for Blood Pressure Control (ADDRESS-BP) in Blacks | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 44 studies in Hypertension by NYU Langone Health, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will develop and evaluate a multilevel implementation strategy to improve management of hard-to-control hypertension among low-income adults receiving care at the Family Health Centers at NYU Langone Health, a network of federally qualified health centers (FQHCs) in New York City.
Using a hybrid mixed-methods implementation science design, the study will be conducted across 9 primary care locations over three phases: a pre-implementation phase to identify contextual barriers using the Consolidated Framework for Implementation Research (CFIR); an implementation phase to deploy and evaluate a multilevel care model; and a post-implementation phase to develop a pragmatic toolkit for scale-up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants who attend FHCs assigned to receive the multilevel care model intervention.
Behavioral: Multilevel Hypertension Care Model
Participants who attend FHCs that were not assigned to receive the multilevel care model intervention.
The intervention is delivered through the existing My Virtual Care (MVC) Epic-integrated team-based virtual high-risk clinic infrastructure and is adapted specifically for patients with hard-to-control hypertension. It is organized across four levels: 1. Patient-Level Strategies (Individual delivery, remote and in-person) 2. Provider and Health System-Level Strategies (EHR-embedded) 3. Community-Level Strategies (Individual, CHW-navigated) 4. Implementation Support
Change in Systolic Blood Pressure (SBP)
Time frame: Baseline, Month 6
Time to Treatment Intensification
Defined as the number of days from the index encounter meeting criteria for hard-to-control hypertension to the first prescription of a new antihypertensive class or dose increase of an existing blood pressure medication that was not present at the index encounter.
Time frame: Up to Month 12
Blood Pressure Control - Guideline Metric
Defined as the proportion of patients achieving controlled blood pressure at the guideline-relevant threshold of \<130/80 mmHg.
Time frame: Month 6, Month 12
Blood Pressure Control - Performance Metric
Defined as the proportion of patients achieving controlled blood pressure at the performance metric threshold of \<140/90 mmHg
Time frame: Month 6, Month 12
Use of Mineralocorticoid Antagonists
Proportion of patients who report use of mineralocorticoid antagonists.
Time frame: Up to Month 12
Use of Single-Pill Combinations
Proportion of patients who report use of single-pill combinations.
Time frame: Up to Month 12
Use of Long-acting Thiazide Diuretics
Proportion of patients who report use of long-acting thiazide diuretics.
Time frame: Up to Month 12
Time to Completed Follow-up Visit
Time to completed follow-up visit (remote or in person) after an encounter with hard-to-control hypertension as a marker of care process efficiency.
Time frame: Up to Month 12
Change in Life's Essential 8 Components Score
Assessment of cardiovascular health using eight key components-four lifestyle behaviors and four health factors. Each component is scored from 0 to 100; the total score is the average of the components and ranges from 0-100; higher scores indicate greater cardiovascular health.
Time frame: Baseline, Month 6
Plan to share: Yes — Coded study data may be shared with other researchers for future research related to hypertension management, implementation science, health equity, cardiovascular outcomes, and health-related social needs in safety-net settings, for participants who consent to optional future data storage and use. Shared data will not include direct identifiers. The link between the code and participant identity will remain with the Principal Investigator at NYU Langone Health and will not be shared with outside researchers. Such data may become available after completion of the study and publication of the primary study findings. Data may be retained indefinitely by NYU Langone Health, subject to participant consent for optional future data storage and use, institutional policies, sponsor requirements, IRB requirements, and applicable confidentiality protections. Participants may withdraw permission for future use, after which stored data will not be used for new analyses.
Supporting information: Study protocol
Time frame: Coded study data may become available after completion of the study and publication of the primary study findings. Data may be retained indefinitely by NYU Langone Health, subject to participant consent for optional future data storage and use, NYU Langone institutional policies, AstraZeneca sponsor requirements, IRB requirements, and applicable confidentiality protections. Participants may withdraw permission for future use, after which stored data will not be used for new analyses.
Access criteria: Access will be limited to qualified researchers whose proposed use of the coded data is reviewed and approved by the Principal Investigator and/or NYU Langone Health, consistent with institutional policies, IRB requirements, AstraZeneca sponsor requirements, and applicable confidentiality protections. The code key linking data to participant identity will remain with the Principal Investigator at NYU Langone Health and will not be shared with outside researchers. Requests should be directed to Olugbenga.ogedegbe@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.
No publications or documents are linked to this record.
Start is estimated for Feb 2027; primary completion for Jan 2028, 11 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 11 months is below that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.